drugset / Trial / NCT06514313

Clinical Trial of VIM With VIT in Children With Relapsed and Refractory Soft Tissue Sarcoma.

NCT06514313

Phase 2 Recruiting 110 enrolled Yizhuo Zhang
RandomizedParallel-groupOpen-labelTreatment

Summary

Explore the efficacy and safety of mitoxantrone liposome combined with irinotecan and vincristine (VIM) in the treatment of relapsed/refractory soft tissue sarcoma in children.

Timeline

Start
2024-07-03
Primary completion
2026-08-01
Completion
2026-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Mitoxantrone Small molecule Intravenous
Comparator Temozolomide Small molecule
Comparator Irinotecan Small molecule
Comparator Vincristine Small molecule

Indications